公开(公告)号：US20240002841A1

公开(公告)日：2024-01-04

申请号：US18329503

申请日：2023-06-05

申请人： Octapharma AG

发明人： Karina Nawrath ,  Janine Guendel ,  Sven Bahrke ,  Lars Stoeckl ,  Steffen Goletz

IPC分类号： C12N15/11 ,  C12N9/64 ,  C12N15/10 ,  C12P21/00 ,  C12N9/22

CPC分类号： C12N15/11 ,  C12Y304/21021 ,  C12N9/6437 ,  C12N15/102 ,  C12P21/005 ,  C12N9/22 ,  C12N2310/20 ,  C12N15/1137

摘要： The present invention relates to a method of modifying at least one gene in a cell via CRISPR/Cas, wherein the at least one gene has at least three alleles. The present invention further relates to cells obtainable by the method of the invention. Additionally, the present invention provides a method of producing a protein in a cell obtainable by the method of modifying at least one gene of the invention. Moreover, the invention relates to proteins obtainable by the method of producing a protein and use thereof, for example in therapy.

公开(公告)号：US11191833B2

公开(公告)日：2021-12-07

申请号：US16308356

申请日：2017-06-12

申请人： OCTAPHARMA AG

发明人： Karin Ahrer ,  Waltraud Kaar ,  Ulrich Roessl

IPC分类号： A61K39/395 ,  A61K47/18 ,  A61K9/00 ,  A61K9/08 ,  A61K47/22 ,  A61K39/00

摘要： The present invention relates to a liquid composition comprising polyclonal immunoglobulins, at least one viscosity modulating amino acid, selected from arginine and histidine, and at least one stabilising amino acid, selected from glycine and proline, wherein more than 90% of the polyclonal immunoglobulins are in the form of monomers or dimers and less than 5% in the form of polymers, and wherein the immunoglobulin concentration in the composition is above 160 g/L and the pH is in the range from 5.2 to 5.9. The invention further relates to a liquid composition for use in medical treatment, to amino acids for formulating a highly concentrated polyclonal immunoglobulins as well as a method of formulating.

公开(公告)号：US20210275644A1

公开(公告)日：2021-09-09

申请号：US17326709

申请日：2021-05-21

申请人： OCTAPHARMA AG

发明人： Christoph KANNICHT ,  Stefan WINGE ,  Guido KOHLA ,  Barbara SOLECKA-WITULSKA

IPC分类号： A61K38/37 ,  C07K14/745 ,  C07K14/755 ,  A61P7/04 ,  C12N15/62

摘要： The invention relates to a glycosylated polypeptide comprising an amino acid sequence being identical or homologous to at least a fragment of a mammalian, preferably a human protein, wherein said glycosylated polypeptide contains one or more sialylated O-glycans and wherein the glycosylated polypeptide shows an increased binding affinity to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9 compared to the mammalian protein or fragment thereof. The invention further relates to composition comprising a first and a second polypeptide, wherein the first polypeptide is a glycosylated polypeptide containing one or more sialylated O-glycans and the second polypeptide contains an amino acid sequence homologous or identical to a second mammalian, in particular human protein, wherein compared to the second polypeptide the composition has an increased binding affinity to a SIGLEC selected from to one or more SIGLECs, selected from SIG-5, SIG-7, SIG-8, and SIG-9.

公开(公告)号：US10251940B2

公开(公告)日：2019-04-09

申请号：US15316711

申请日：2015-06-08

申请人： OCTAPHARMA AG

发明人： Christoph Kannicht ,  Barbara Solecka ,  Guido Kohla ,  Stefan Winge

IPC分类号： A61K38/00 ,  A61K38/36 ,  C07K14/755 ,  A61P7/04 ,  A61K38/37 ,  C07K1/34 ,  C12P21/02 ,  C12P21/06

摘要： A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.

公开(公告)号：US10214575B2

公开(公告)日：2019-02-26

申请号：US15256288

申请日：2016-09-02

申请人： OCTAPHARMA AG

发明人： Gustav Gilljam ,  Stefan Winge ,  Maya Tiemeyer

IPC分类号： C07K1/16 ,  C07K1/36 ,  B01D15/32 ,  B01D15/34 ,  B01D15/36 ,  B01D15/38 ,  C07K14/52 ,  C07K14/475 ,  C07K14/535 ,  C07K14/575

摘要： A method of purifying a Growth Factor Protein in a purification sequence employing chromatography is provided. The method comprises performing at least one chromatography step using a multimodal resin, binding the Growth Factor Protein to the multimodal resin at a pH from 4 to 6.2, and eluting the Growth Factor Protein at a pH in the range of from 5.5 to 6.5. The elution of Growth Factor Protein is improved by addition of arginine and/or NaCl in the eluting buffer. Optionally the multimodal resin step is followed by a yeast derived affinity ligand resin step, which results in a purity of the product greater than 90%.

公开(公告)号：US20180185455A1

公开(公告)日：2018-07-05

申请号：US15316711

申请日：2015-06-08

申请人： OCTAPHARMA AG

发明人： Christoph KANNICHT ,  Barbara SOLECKA ,  Guido KOHLA ,  Stefan WINGE

IPC分类号： A61K38/36 ,  A61P7/04 ,  A61K38/37 ,  C07K14/755 ,  C07K1/34 ,  C12P21/06 ,  C12P21/02

CPC分类号： A61K38/36 ,  A61K38/37 ,  A61P7/04 ,  C07K1/34 ,  C07K14/755 ,  C12P21/02 ,  C12P21/06

摘要： A composition comprising a complex of Factor VIII and one or more Von Willebrand Factor peptides, wherein the Von Willebrand Factor peptides comprise at least the amino acids 764 to 1035 and 1691 to 1905 of SEQ ID No. 1 but not amino acids 2255 to 2645 of SEQ ID No. 1.

公开(公告)号：US09901597B2

公开(公告)日：2018-02-27

申请号：US13980894

申请日：2012-02-03

申请人： Waltraud Kaar ,  Alfred Zochling ,  Karin Ahrer

发明人： Waltraud Kaar ,  Alfred Zochling ,  Karin Ahrer

IPC分类号： A61K35/14 ,  A61K35/16 ,  C07K16/00 ,  C07K14/76

CPC分类号： C07K16/00 ,  A61K35/14 ,  A61K35/16 ,  C07K14/76

摘要： A method for inactivation or removal of coagulation factors FII, FVII, FVIIa, FIX, FIXa, FX, FXI and FXIa in or from protein containing solutions obtained from blood, blood plasma, plasma fractions or by recombinant means wherein the protein containing solution is contacted with an organic acid or its salt while being stirred.

公开(公告)号：US09512457B2

公开(公告)日：2016-12-06

申请号：US15011760

申请日：2016-02-01

申请人： Carola Schroeder ,  Haiyan Ding ,  Cathleen Wegmann

发明人： Carola Schroeder ,  Haiyan Ding ,  Cathleen Wegmann

IPC分类号： C12P21/02 ,  C12P21/00 ,  C07K14/535 ,  C07K14/755 ,  C07K14/81 ,  C12N9/64 ,  C12N15/85 ,  C07K14/505 ,  C07K14/54

CPC分类号： C12N15/85 ,  C07K14/505 ,  C07K14/535 ,  C07K14/54 ,  C07K14/755 ,  C07K14/8125 ,  C12N9/6427 ,  C12N9/6437 ,  C12N9/644 ,  C12N2820/007 ,  C12N2820/60 ,  C12P21/00 ,  C12P21/02 ,  C12Y304/21001 ,  C12Y304/21021 ,  C12Y304/21022

摘要： The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.

摘要翻译： 本发明涉及一种用于在无血清条件下稳定转染的永生化人细胞系的无血清生成改进方法，所述方法具有携带编码感兴趣蛋白质的基因的特异性载体。 此外，本发明涉及通过所述方法获得的生产细胞系，利用所述生产细胞系的所述感兴趣的蛋白质的生产方法和携带感兴趣的基因的特异性载体本身。

公开(公告)号：US20160177362A1

公开(公告)日：2016-06-23

申请号：US15011760

申请日：2016-02-01

申请人： Carola Schroeder ,  Haiyan Ding ,  Cathleen Wegmann

发明人： Carola Schroeder ,  Haiyan Ding ,  Cathleen Wegmann

IPC分类号： C12P21/00 ,  C07K14/54 ,  C07K14/81 ,  C12N9/64 ,  C07K14/535 ,  C07K14/505 ,  C07K14/755

CPC分类号： C12N15/85 ,  C07K14/505 ,  C07K14/535 ,  C07K14/54 ,  C07K14/755 ,  C07K14/8125 ,  C12N9/6427 ,  C12N9/6437 ,  C12N9/644 ,  C12N2820/007 ,  C12N2820/60 ,  C12P21/00 ,  C12P21/02 ,  C12Y304/21001 ,  C12Y304/21021 ,  C12Y304/21022

摘要： The present invention relates to an improved method for the serum-free production of an immortalized human cell line stably transfected under serum-free conditions with a specific vector carrying the gene coding for the protein of interest. Furthermore the invention relates to a production cell line obtained by said method, a production method for said protein of interest utilizing said production cell line, and the specific vector carrying the gene of interest itself.

摘要翻译： 本发明涉及一种用于在无血清条件下稳定转染的永生化人细胞系的无血清生成改进方法，所述方法具有携带编码感兴趣蛋白质的基因的特异性载体。 此外，本发明涉及通过所述方法获得的生产细胞系，利用所述生产细胞系的所述感兴趣的蛋白质的生产方法和携带感兴趣的基因的特异性载体本身。

公开(公告)号：US20150250879A1

公开(公告)日：2015-09-10

申请号：US14431498

申请日：2013-09-26

申请人： OCTAPHARMA AG

发明人： Andrea Heger ,  Tor-Einar Svae ,  Juergen Roemisch ,  Alfred Zoechling

IPC分类号： A61K47/18 ,  C07K16/18 ,  G01N33/49

CPC分类号： A61K47/183 ,  A61K39/39591 ,  C07K16/00 ,  C07K16/18 ,  G01N33/49 ,  G01N33/80

摘要： A non-hemolytic acidic composition comprising an immunoglobulin selected from immunoglobulin A, immunoglobulin G or immunoglobulin M at a pH value in the range of 4.65 to 5.7 comprising one or more excipients selected from amino acids, sugars and sugar alcohols in a concentration range of 100-350 mmol/l, in particular 200-350 mmol/l, characterized in that it displays an optical density (OD) in the range of 0.14 to −0.1 when the OD is determined in a spectrophotometer at 414 nm at a film thickness of 0.825 mm; and its use in an assay for determination of the hemolytic potential of intravenously applied pharmaceuticals and compositions and preparations displaying a reduced potential of hemolysis when being applied intravenously.

摘要翻译： 一种非溶血酸性组合物，其包含选自免疫球蛋白A，免疫球蛋白G或免疫球蛋白M的免疫球蛋白，其pH值在4.65至5.7范围内，包含一种或多种选自浓度范围为100的氨基酸，糖和糖醇的赋形剂 -350mmol / l，特别是200-350mmol / l，其特征在于当在分光光度计中在414nm处测定OD时，它的光密度（OD）在0.14至-0.1的范围内，膜厚度 0.825毫米; 并且其用于测定静脉内施用的药物和组合物和制剂的溶血潜力的测定法，其在静脉内施用时显示出降低的溶血潜力。